• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于评估疼痛患者便秘情况的肠道功能指数:非便秘疼痛患者群体参考范围的定义

The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients.

作者信息

Ueberall M A, Müller-Lissner S, Buschmann-Kramm C, Bosse B

机构信息

Institut für Neurowissenschaften, Algesiologie und Pädiatrie-IFNAP, Nuremberg, Germany.

出版信息

J Int Med Res. 2011;39(1):41-50. doi: 10.1177/147323001103900106.

DOI:10.1177/147323001103900106
PMID:21672306
Abstract

Opioid-induced constipation (OIC) is a severe, persisting side-effect of opioid therapy. The Bowel Function Index (BFI(a), numerical analogue scale 0 - 100), calculated as the mean of three variables (ease of defaecation, feeling of incomplete bowel evacuation, and personal judgement of constipation) was developed to evaluate bowel function in opioid-treated patients with pain. This clinician-administered tool allows easy measurement of OIC from the patient's perspective. The purpose of this investigation was to define a reference range reflecting BFI values in non-constipated chronic pain patients who were recruited into a cross-sectional survey and asked for their perceptions of constipation. The BFI scores were assessed and compared with those of patients with confirmed OIC obtained from two previously published trials. Results were analysed and a reference range of BFI values of 0 - 28.8, into which 95% of non-constipated chronic pain patients fell, was defined. This permits discrimination between chronic pain patients with, or without, constipation.

摘要

阿片类药物引起的便秘(OIC)是阿片类药物治疗的一种严重且持续存在的副作用。肠道功能指数(BFI(a),数字模拟量表0 - 100)由三个变量(排便难易程度、排便不尽感和便秘的个人判断)的平均值计算得出,用于评估接受阿片类药物治疗的疼痛患者的肠道功能。这种由临床医生操作的工具能够从患者角度轻松测量OIC。本研究的目的是确定一个反映非便秘慢性疼痛患者BFI值的参考范围,这些患者被纳入一项横断面调查,并被询问其便秘感受。对BFI评分进行了评估,并与之前两项已发表试验中确诊为OIC的患者的评分进行了比较。对结果进行分析后,确定了BFI值的参考范围为0 - 28.8,95%的非便秘慢性疼痛患者的BFI值落在该范围内。这有助于区分有无便秘的慢性疼痛患者。

相似文献

1
The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients.用于评估疼痛患者便秘情况的肠道功能指数:非便秘疼痛患者群体参考范围的定义
J Int Med Res. 2011;39(1):41-50. doi: 10.1177/147323001103900106.
2
Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].与既往镇痛治疗相比,患者对长效羟考酮/纳洛酮治疗后生活质量(QoL)及阿片类药物引起的便秘(OIC)减少情况的偏好[PREFER研究]
Int J Clin Pract. 2014 Nov;68(11):1364-75. doi: 10.1111/ijcp.12468. Epub 2014 May 23.
3
Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.对于慢性重度疼痛且泻药难治性便秘的患者,与缓释羟考酮相比,使用缓释羟考酮/纳洛酮治疗可改善疼痛缓解情况及阿片类药物所致便秘。
Clin Ther. 2015 Apr 1;37(4):784-92. doi: 10.1016/j.clinthera.2015.02.010. Epub 2015 Mar 7.
4
Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.盐酸羟考酮/纳洛酮控释片治疗神经病理性疼痛的疗效观察-来自一项大型观察性研究。
Expert Opin Pharmacother. 2012 Feb;13(3):299-311. doi: 10.1517/14656566.2012.648615. Epub 2012 Jan 6.
5
Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives.固定剂量阿片激动剂/拮抗剂对长期使用阿片类药物治疗非恶性疼痛且不能耐受泻药的患者便秘的影响。
Pain Physician. 2014 Sep-Oct;17(5):415-24.
6
Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.口服羟考酮及羟考酮/纳洛酮组合用于初用阿片类药物的癌症患者的疗效及耐受性:一项倾向分析
Drug Des Devel Ther. 2015 Nov 2;9:5863-72. doi: 10.2147/DDDT.S92998. eCollection 2015.
7
Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.与先前的镇痛治疗相比,缓释羟考酮和纳洛酮治疗可缓解重度疼痛患者阿片类药物引起的便秘。
Curr Med Res Opin. 2017 Dec;33(12):2217-2227. doi: 10.1080/03007995.2017.1367276. Epub 2017 Sep 11.
8
Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation.验证肠道功能指数以检测阿片类药物引起的便秘的临床有意义的变化。
J Med Econ. 2009;12(4):371-83. doi: 10.3111/13696990903430481.
9
Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.接受阿片类药物治疗慢性疼痛患者的生活质量和医疗资源:羟考酮/纳洛酮的地位综述
Clin Drug Investig. 2015 Jan;35(1):1-11. doi: 10.1007/s40261-014-0254-6.
10
The Bowel Function Index: a new validated scale for assessing opioid-induced constipation.肠道功能指数:一种评估阿片类药物引起的便秘的新验证量表。
Curr Med Res Opin. 2012 Mar;28(3):457-66. doi: 10.1185/03007995.2012.657301. Epub 2012 Feb 16.

引用本文的文献

1
Opioid-induced constipation in internal medicine: recognition and management pathways.内科中的阿片类药物引起的便秘:识别与管理途径
Intern Emerg Med. 2025 Aug 28. doi: 10.1007/s11739-025-04091-2.
2
The Relationship Between Opioid Dose and Opioid-Induced Constipation in Japanese Patients With Cancer Pain: A Post Hoc Analysis of a Prospective Observational Cohort Study.日本癌症疼痛患者中阿片类药物剂量与阿片类药物所致便秘的关系:一项前瞻性观察队列研究的事后分析
Cureus. 2025 Jul 10;17(7):e87697. doi: 10.7759/cureus.87697. eCollection 2025 Jul.
3
Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
纳地美定用于癌症患者阿片类药物所致便秘的多中心、双盲、随机、安慰剂对照试验
J Clin Oncol. 2024 Dec 10;42(35):4206-4217. doi: 10.1200/JCO.24.00381. Epub 2024 Sep 10.
4
Managing Severe Cancer Pain with Oxycodone/Naloxone Treatment: A Literature Review Update.用羟考酮/纳洛酮治疗管理重度癌痛:文献综述更新
J Pers Med. 2024 May 1;14(5):483. doi: 10.3390/jpm14050483.
5
Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol.一项多中心、双盲、随机、安慰剂对照试验的原理与设计,旨在研究纳地美定对癌症疼痛患者阿片类药物所致便秘的影响:一项研究方案。
Contemp Clin Trials Commun. 2022 Aug 5;29:100967. doi: 10.1016/j.conctc.2022.100967. eCollection 2022 Oct.
6
Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain.纳地美定在慢性非癌性疼痛患者阿片类药物所致便秘中作用的最新进展
Therap Adv Gastroenterol. 2022 Apr 28;15:17562848221078638. doi: 10.1177/17562848221078638. eCollection 2022.
7
Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?纳洛昔醇疗法能否改善晚期癌症患者的生活质量?
Cancers (Basel). 2021 Nov 16;13(22):5736. doi: 10.3390/cancers13225736.
8
Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J Study): A Post Hoc Analysis.日本癌症疼痛患者的阿片类药物引起的便秘(OIC-J研究):一项事后分析。
J Clin Med. 2021 Sep 16;10(18):4193. doi: 10.3390/jcm10184193.
9
Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.阿片类药物引起的便秘和肠道功能障碍的管理:意大利多学科专家组的专家意见。
Adv Ther. 2021 Jul;38(7):3589-3621. doi: 10.1007/s12325-021-01766-y. Epub 2021 Jun 4.
10
Proposed Criteria for Constipation in Palliative Care Patients. A Multicenter Cohort Study.姑息治疗患者便秘的拟议标准。一项多中心队列研究。
J Clin Med. 2020 Dec 25;10(1):40. doi: 10.3390/jcm10010040.